Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 382

1.

Put on Your Para-spectacles: The Development of Optimized CRISPR-Cas13-Based Approaches to Image RNA Dynamics in Real Time.

Davis BJ, O'Connell MR.

Mol Cell. 2020 Jan 16;77(2):207-209. doi: 10.1016/j.molcel.2019.12.018.

PMID:
31951545
2.

Associations of Environmental Conditions and Vibrio parahaemolyticus Genetic Markers in Washington State Pacific Oysters.

Flynn A, Davis BJK, Atherly E, Olson G, Bowers JC, DePaola A, Curriero FC.

Front Microbiol. 2019 Dec 4;10:2797. doi: 10.3389/fmicb.2019.02797. eCollection 2019.

3.

Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.

Wang M, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Ferreira RB, Chiang CW, Guryanova OA, Kopinke D, Heldermon CD, Castellano RK, Law BK.

Cell Death Discov. 2019 Dec 10;5:153. doi: 10.1038/s41420-019-0228-9. eCollection 2019.

4.

Development and Evaluation of Geostatistical Methods for Non-Euclidean-Based Spatial Covariance Matrices.

Davis BJK, Curriero FC.

Math Geosci. 2019 Aug;51(6):767-791. doi: 10.1007/s11004-019-09791-y. Epub 2019 Mar 14.

PMID:
31827631
5.

c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner.

Henderson-Redmond AN, Nealon CM, Davis BJ, Yuill MB, Sepulveda DE, Blanton HL, Piscura MK, Zee ML, Haskins CP, Marcus DJ, Mackie K, Guindon J, Morgan DJ.

Neuropharmacology. 2020 Mar 1;164:107847. doi: 10.1016/j.neuropharm.2019.107847. Epub 2019 Nov 20.

PMID:
31758947
6.

Performance of cold chains and modeled growth of Vibrio parahaemolyticus for farmed oysters distributed in the United States and internationally.

Love DC, Kuehl LM, Lane RM, Fry JP, Harding J, Davis BJK, Clancy K, Hudson B.

Int J Food Microbiol. 2020 Jan 16;313:108378. doi: 10.1016/j.ijfoodmicro.2019.108378. Epub 2019 Oct 25.

7.

11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities.

Jethwa KR, Hellekson CD, Evans JD, Harmsen WS, Wilhite TJ, Whitaker TJ, Park SS, Choo CR, Stish BJ, Olivier KR, Haloi R, Lowe VJ, Welch BT, Quevedo JF, Mynderse LA, Karnes RJ, Kwon ED, Davis BJ.

Adv Radiat Oncol. 2019 Jul 4;4(4):659-667. doi: 10.1016/j.adro.2019.06.006. eCollection 2019 Oct-Dec.

8.

Withdrawal: Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo : Role of mitochondrial reactive nitrogen species.

Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG 4th, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH.

J Biol Chem. 2019 Sep 6;294(36):13525. doi: 10.1074/jbc.W119.010595. No abstract available.

9.

Vibrio parahaemolyticus in the Chesapeake Bay: Operational In Situ Prediction and Forecast Models Can Benefit from Inclusion of Lagged Water Quality Measurements.

Davis BJK, Jacobs JM, Zaitchik B, DePaola A, Curriero FC.

Appl Environ Microbiol. 2019 Aug 14;85(17). pii: e01007-19. doi: 10.1128/AEM.01007-19. Print 2019 Sep 1.

10.

Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group.

Lieng H, Kneebone A, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L, Holt T, Hruby G, Pryor D, Sidhom M, Skala M, Yaxley J, Shakespeare TP.

Radiother Oncol. 2019 Nov;140:68-75. doi: 10.1016/j.radonc.2019.05.016. Epub 2019 Jun 6.

PMID:
31177044
11.

Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer.

Mason BR, Eastham JA, Davis BJ, Mynderse LA, Pugh TJ, Lee RJ, Ippolito JE.

J Natl Compr Canc Netw. 2019 May 1;17(5):506-513. doi: 10.6004/jnccn.2019.7306.

PMID:
31085758
12.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
13.

Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases.

Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ.

Adv Radiat Oncol. 2019 Feb 19;4(2):314-322. doi: 10.1016/j.adro.2019.02.002. eCollection 2019 Apr-Jun.

14.

Speech production and disorganization in schizotypy: Investigating the role of cognitive and affective systems.

Marggraf MP, Davis BJ, Hardin KL, Abplanalp SJ, Haller JA, DeCrescenzo P, Minor KS.

J Psychiatr Res. 2019 Jul;114:11-16. doi: 10.1016/j.jpsychires.2019.03.023. Epub 2019 Mar 24.

PMID:
30991167
15.

The American Board of Radiology Initial Certification in Radiation Oncology: Moving Forward Through Collaboration.

Wallner PE, Kachnic LA, Alektiar KM, Davis BJ, Hardenbergh PH, Ng AK.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):21-23. doi: 10.1016/j.ijrobp.2019.01.090. No abstract available.

PMID:
30967226
16.

Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence.

Wymer KM, Sharma V, Davis BJ, Kwon ED, Mynderse LA, Karnes RJ.

Clin Genitourin Cancer. 2019 Jun;17(3):e536-e540. doi: 10.1016/j.clgc.2019.01.019. Epub 2019 Feb 6. No abstract available.

PMID:
30902522
17.

Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds.

Merrell KW, Davis BJ, Goulet CC, Furutani KM, Mynderse LA, Harmsen WS, Wilson TM, McLaren RH, Deufel CL, Birckhead BJ, Funk RK, McMenomy BP, Stish BJ, Choo CR.

Brachytherapy. 2019 May - Jun;18(3):306-312. doi: 10.1016/j.brachy.2019.01.007. Epub 2019 Mar 8.

PMID:
30853392
18.

A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.

Wang M, Ferreira RB, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Sharma A, Avery BA, Rodriguez E, Chiang CW, Narayan S, Heldermon CD, Castellano RK, Law BK.

Oncogene. 2019 May;38(22):4264-4282. doi: 10.1038/s41388-019-0717-6. Epub 2019 Feb 4.

PMID:
30718919
19.

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.

Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ, Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED, Davis BJ, Nathan MA.

Adv Radiat Oncol. 2018 Sep 5;4(1):79-89. doi: 10.1016/j.adro.2018.08.022. eCollection 2019 Jan-Mar.

20.

Performance of Cold Chains for Chesapeake Bay Farmed Oysters and Modeled Growth of Vibrio parahaemolyticus.

Love DC, Lane RM, Davis BJK, Clancy K, Fry JP, Harding J, Hudson B.

J Food Prot. 2019 Jan;82(1):168-178. doi: 10.4315/0362-028X.JFP-18-044.

PMID:
30702938
21.

Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures.

Erlanson DA, Davis BJ, Jahnke W.

Cell Chem Biol. 2019 Jan 17;26(1):9-15. doi: 10.1016/j.chembiol.2018.10.001. Epub 2018 Oct 25. Review.

22.

Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.

Routman DM, Funk RK, Stish BJ, Mynderse LA, Wilson TM, McLaren R, Harmsen WS, Mara K, Deufel CL, Furutani KM, Haddock MG, Pisansky TM, Choo CR, Davis BJ.

Brachytherapy. 2019 Jan - Feb;18(1):1-7. doi: 10.1016/j.brachy.2018.09.003. Epub 2018 Oct 4.

PMID:
30293836
23.

Quantification of Blood Velocity with 4D Digital Subtraction Angiography Using the Shifted Least-Squares Method.

Wu Y, Shaughnessy G, Hoffman CA, Oberstar EL, Schafer S, Schubert T, Ruedinger KL, Davis BJ, Mistretta CA, Strother CM, Speidel MA.

AJNR Am J Neuroradiol. 2018 Oct;39(10):1871-1877. doi: 10.3174/ajnr.A5793. Epub 2018 Sep 13.

24.

The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines.

Chang AJ, McBride S, Keyes M, Chung HT, Davis BJ, Cox BW, Crook J, Demanes DJ, Hsu IC, Kamrava M, Krauss DJ, Morton G, Orio Iii PF, Roach Iii M, Venkat PS, Vigneault E, Zelefsky MJ.

J Clin Oncol. 2018 Sep 13:JCO1800626. doi: 10.1200/JCO.18.00626. [Epub ahead of print] No abstract available.

PMID:
30212298
25.

Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT.

Evans JD, Morris LK, Zhang H, Cao S, Liu X, Mara KC, Stish BJ, Davis BJ, Mansfield AS, Dronca RS, Iott MJ, Kwon ED, Foote RL, Olivier KR, Dong H, Park SS.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):229-240. doi: 10.1016/j.ijrobp.2018.09.001. Epub 2018 Sep 8.

26.

α1L-adrenoceptors mediate contraction of human erectile tissue.

Davis BJ, Chapple CR, Sellers DJ, Naylor AL, Sillar D, Campbell A, Chess-Williams R.

J Pharmacol Sci. 2018 Aug;137(4):366-371. doi: 10.1016/j.jphs.2018.08.003. Epub 2018 Aug 9.

27.

Low dose rate prostate brachytherapy.

Stish BJ, Davis BJ, Mynderse LA, McLaren RH, Deufel CL, Choo R.

Transl Androl Urol. 2018 Jun;7(3):341-356. doi: 10.21037/tau.2017.12.15. Review.

28.

Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group.

Lieng H, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L, Holt T, Hruby G, Pryor D, Shakespeare TP, Sidhom M, Skala M, Wiltshire K, Yaxley J, Kneebone A.

Radiother Oncol. 2018 Nov;129(2):377-386. doi: 10.1016/j.radonc.2018.06.027. Epub 2018 Jul 20.

PMID:
30037499
29.

ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer.

Expert Panel on Urologic Imaging:, Froemming AT, Verma S, Eberhardt SC, Oto A, Alexander LF, Allen BC, Coakley FV, Davis BJ, Fulgham PF, Hosseinzadeh K, Porter C, Sahni VA, Schuster DM, Showalter TN, Venkatesan AM, Wang CL, Remer EM.

J Am Coll Radiol. 2018 May;15(5S):S132-S149. doi: 10.1016/j.jacr.2018.03.019.

PMID:
29724417
30.

The role of signals in two variations of differential-reinforcement-of-low-rate procedures.

Becraft JL, Borrero JC, Davis BJ, Mendres-Smith AE, Castillo MI.

J Appl Behav Anal. 2018 Jan;51(1):3-24. doi: 10.1002/jaba.431. Epub 2018 Jan 3.

PMID:
29313972
31.

Words matter: Implementing the electronically activated recorder in schizotypy.

Minor KS, Davis BJ, Marggraf MP, Luther L, Robbins ML.

Personal Disord. 2018 Mar;9(2):133-143. doi: 10.1037/per0000266. Epub 2017 Dec 7.

PMID:
29215902
32.

ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II.

Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ.

Adv Radiat Oncol. 2017 Mar 20;2(3):437-454. doi: 10.1016/j.adro.2017.03.003. eCollection 2017 Jul-Sep. Review.

33.

Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease.

Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, Davis BJ.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):28-39. doi: 10.1016/j.prro.2017.07.011. Epub 2017 Jul 20. Review.

34.

Semantic coherence in psychometric schizotypy: An investigation using Latent Semantic Analysis.

Marggraf MP, Cohen AS, Davis BJ, DeCrescenzo P, Bair N, Minor KS.

Psychiatry Res. 2018 Jan;259:63-67. doi: 10.1016/j.psychres.2017.09.078. Epub 2017 Sep 30.

PMID:
29028526
35.

Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging.

Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ.

J Urol. 2018 Mar;199(3):726-733. doi: 10.1016/j.juro.2017.09.033. Epub 2017 Sep 12.

PMID:
28916273
36.

Environmental Determinants of Vibrio parahaemolyticus in the Chesapeake Bay.

Davis BJK, Jacobs JM, Davis MF, Schwab KJ, DePaola A, Curriero FC.

Appl Environ Microbiol. 2017 Oct 17;83(21). pii: e01147-17. doi: 10.1128/AEM.01147-17. Print 2017 Nov 1.

37.

ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.

Expert Panel on Radiation Oncology-Prostate:, Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ.

Adv Radiat Oncol. 2016 Oct 20;2(1):62-84. doi: 10.1016/j.adro.2016.10.002. eCollection 2017 Jan-Mar. Review. No abstract available.

38.

Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis.

Schnakenberg Martin AM, Bonfils KA, Davis BJ, Smith EA, Schuder K, Lysaker PH.

Schizophr Res Cogn. 2016 Oct 10;6:15-21. doi: 10.1016/j.scog.2016.09.001. eCollection 2016 Dec.

39.

The evolution of brachytherapy for prostate cancer.

Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, Hoskin PJ, Yoshioka Y, Morton GC, Horwitz EM.

Nat Rev Urol. 2017 Jun 30;14(7):415-439. doi: 10.1038/nrurol.2017.76. Review.

PMID:
28664931
40.

Sternum First, Perhaps Pelvis Later.

Davis BJ, Park SS.

Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):496. doi: 10.1016/j.ijrobp.2017.04.020. No abstract available.

PMID:
28581389
41.

Brachytherapy in the Management of Prostate Cancer.

Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R.

Surg Oncol Clin N Am. 2017 Jul;26(3):491-513. doi: 10.1016/j.soc.2017.01.008. Epub 2017 May 11. Review.

PMID:
28576185
42.

Renal Mass and Localized Renal Cancer: AUA Guideline.

Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, Clark PE, Davis BJ, Derweesh IH, Giambarresi L, Gervais DA, Hu SL, Lane BR, Leibovich BC, Pierorazio PM.

J Urol. 2017 Sep;198(3):520-529. doi: 10.1016/j.juro.2017.04.100. Epub 2017 May 4.

PMID:
28479239
43.

ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.

Expert Panel on Urologic Imaging:, Coakley FV, Oto A, Alexander LF, Allen BC, Davis BJ, Froemming AT, Fulgham PF, Hosseinzadeh K, Porter C, Sahni VA, Schuster DM, Showalter TN, Venkatesan AM, Verma S, Wang CL, Remer EM, Eberhardt SC.

J Am Coll Radiol. 2017 May;14(5S):S245-S257. doi: 10.1016/j.jacr.2017.02.026. Review.

PMID:
28473080
44.

Mice expressing a "hyper-sensitive" form of the CB1 cannabinoid receptor (CB1) show modestly enhanced alcohol preference and consumption.

Marcus DJ, Henderson-Redmond AN, Gonek M, Zee ML, Farnsworth JC, Amin RA, Andrews MJ, Davis BJ, Mackie K, Morgan DJ.

PLoS One. 2017 Apr 20;12(4):e0174826. doi: 10.1371/journal.pone.0174826. eCollection 2017.

45.

Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.

Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK.

Oncotarget. 2017 Apr 25;8(17):28971-28989. doi: 10.18632/oncotarget.15952.

46.

Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.

Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):526-535. doi: 10.1016/j.ijrobp.2016.11.014. Epub 2016 Nov 17.

47.

Feasibility of reduced-dose three-dimensional/four-dimensional-digital subtraction angiogram using a weighted edge preserving filter.

Oberstar EL, Speidel MA, Davis BJ, Strother CM, Mistretta CA.

J Med Imaging (Bellingham). 2017 Jan;4(1):013501. doi: 10.1117/1.JMI.4.1.013501. Epub 2017 Jan 11.

48.

ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer.

McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ; Expert Panel on Radiation OncologyProstate.

Am J Clin Oncol. 2017 Feb;40(1):1-10. doi: 10.1097/COC.0000000000000354.

PMID:
28059930
49.

ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer.

Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N.

Brachytherapy. 2017 Mar - Apr;16(2):266-276. doi: 10.1016/j.brachy.2016.10.002. Epub 2016 Dec 7.

PMID:
27964905

Supplemental Content

Loading ...
Support Center